John Heymach, MD, PhD, MD Anderson Cancer Center

Articles by John Heymach, MD, PhD, MD Anderson Cancer Center

Expert on lung cancer

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

ByJohn Heymach, MD, PhD, MD Anderson Cancer Center

May 19th 2023

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Latest Updated Articles

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC
May 19th 2023

Trending on OncLive

FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma

FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma

The OncFive: Top Oncology Articles for the Week of 8/9

Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer

Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera